LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients
A Phase 0/2 Study of LY3214996 (ERK Inhibitor) in Combination With Abemaciclib (CDK4 and 6 Inhibitor) in Recurrent Glioblastoma Participants Scheduled for Resection to Evaluate Central Nervous System (CNS) Penetration
Sponsor: Barrow Neurological Institute
This EARLY_PHASE1 trial investigates GBM and Glioblastoma and is currently completed. Barrow Neurological Institute leads this study, which shows 11 recorded versions since 2020 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
11 versions recorded-
Mar 2026 — Present [monthly]
Completed EARLY_PHASE1
Status: Active Not Recruiting → Completed
-
Jun 2025 — Mar 2026 [monthly]
Active Not Recruiting EARLY_PHASE1
-
Mar 2025 — Jun 2025 [monthly]
Active Not Recruiting EARLY_PHASE1
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Mar 2025 [monthly]
Recruiting EARLY_PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting EARLY_PHASE1
▶ Show 6 earlier versions
-
Apr 2024 — Jul 2024 [monthly]
Recruiting EARLY_PHASE1
-
Apr 2023 — Apr 2024 [monthly]
Recruiting EARLY_PHASE1
-
Apr 2022 — Apr 2023 [monthly]
Recruiting EARLY_PHASE1
-
Jan 2021 — Apr 2022 [monthly]
Recruiting EARLY_PHASE1
-
Aug 2020 — Jan 2021 [monthly]
Recruiting EARLY_PHASE1
-
Jun 2020 — Aug 2020 [monthly]
Recruiting EARLY_PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Barrow Neurological Institute
- Eli Lilly and Company
- Ivy Brain Tumor Center
- Nader Sanai
For direct contact, visit the study record on ClinicalTrials.gov .